HLA Allele Frequencies in 5802 Koreans: Varied Allele Types Associated with SJS/TEN According to Culprit Drugs
Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) are very serious forms of drug-induced cutaneous adverse reaction. SJS/TEN induced by certain drug is well known to be associated with some human leukocyte antigen (HLA) gene type. We aimed to explore HLA allele frequencies and thei...
Saved in:
Published in | Yonsei medical journal Vol. 57; no. 1; pp. 118 - 126 |
---|---|
Main Authors | , , , , , , |
Format | Journal Article |
Language | English |
Published |
Korea (South)
Yonsei University College of Medicine
01.01.2016
연세대학교의과대학 |
Subjects | |
Online Access | Get full text |
ISSN | 0513-5796 1976-2437 1976-2437 |
DOI | 10.3349/ymj.2016.57.1.118 |
Cover
Loading…
Abstract | Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) are very serious forms of drug-induced cutaneous adverse reaction. SJS/TEN induced by certain drug is well known to be associated with some human leukocyte antigen (HLA) gene type. We aimed to explore HLA allele frequencies and their association with SJS/TEN according to culprit drugs in Korea.
We enrolled 5802 subjects who had results of HLA typing test from August 2005 to July 2014. Total 28 SJS/TEN patients were categorized based on culprit drugs (allopurinol, lamotrigine, carbamazepine) and identified the presence of HLA-B*58:01, HLA-B*44:03, HLA-B*15:02, and HLA-A*31:01.
HLA-A*24:02 (20.5%), HLA-B*44:03 (10.0%), and HLA-Cw*01:02 (17.1%) were the most frequent type in HLA-A, -B, and -C genes, respectively. Allele frequencies of HLA-B*58:01, HLA-B*44:03, HLA-A*31:01, and HLA-B*15:02 were 7.0%, 10.0%, 5.0%, and 0.3%, respectively. In 958 allopurinol users, 9 subjects (0.9%) were diagnosed with SJS/TEN. Among them, 8 subjects possessed HLA-B*58:01 allele. SJS/TEN induced by allopurinol was more frequently developed in subjects with HLA-B*58:01 than in subjects without it [odds ratio: 57.4; confidence interval (CI) 7.12-463.50; p<0.001]. Allopurinol treatment, based on screening by HLA-B*58:01 genotyping, could be more cost-effective than that not based on screening. HLA-B*44:03 may be associated with lamotrigine-induced SJS/TEN (odds ratio: 12.75; CI 1.03-157.14; p=0.053). Among carbamazepine users, only two patients experienced SJS/TEN and possessed neither HLA-B*15:02 nor HLA-A*31:03.
HLA gene frequencies varied in Korea. Screening of HLA-B*58:01 before the use of allopurinol might be needed to anticipate probability of SJS/TEN. |
---|---|
AbstractList | Purpose: Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) are very serious forms of drug-induced cutaneousadverse reaction. SJS/TEN induced by certain drug is well known to be associated with some human leukocyte antigen (HLA) gene type. We aimed to explore HLA allele frequencies and their association with SJS/TEN according to culprit drugs in Korea.
Materials and Methods: We enrolled 5802 subjects who had results of HLA typing test from August 2005 to July 2014. Total 28 SJS/TEN patients were categorized based on culprit drugs (allopurinol, lamotrigine, carbamazepine) and identified the presence of HLA-B*58:01, HLA-B*44:03, HLA-B*15:02, and HLA-A*31:01.
Results: HLA-A*24:02 (20.5%), HLA-B*44:03 (10.0%), and HLA-Cw*01:02 (17.1%) were the most frequent type in HLA-A, -B, and -C genes, respectively. Allele frequencies of HLA-B*58:01, HLA-B*44:03, HLA-A*31:01, and HLA-B*15:02 were 7.0%, 10.0%, 5.0%, and 0.3%, respectively. In 958 allopurinol users, 9 subjects (0.9%) were diagnosed with SJS/TEN. Among them, 8 subjects possessedHLA-B*58:01 allele. SJS/TEN induced by allopurinol was more frequently developed in subjects with HLA-B*58:01 than in subjects without it [odds ratio: 57.4; confidence interval (CI) 7.12–463.50; p<0.001]. Allopurinol treatment, based on screening by HLA-B*58:01 genotyping, could be more cost-effective than that not based on screening. HLA-B*44:03 may be associated with lamotrigine-induced SJS/TEN (odds ratio: 12.75; CI 1.03–157.14; p=0.053). Among carbamazepine users, only two patients experiencedSJS/TEN and possessed neither HLA-B*15:02 nor HLA-A*31:03.
Conclusion: HLA gene frequencies varied in Korea. Screening of HLA-B*58:01 before the use of allopurinol might be needed to anticipate probability of SJS/TEN. KCI Citation Count: 16 Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) are very serious forms of drug-induced cutaneous adverse reaction. SJS/TEN induced by certain drug is well known to be associated with some human leukocyte antigen (HLA) gene type. We aimed to explore HLA allele frequencies and their association with SJS/TEN according to culprit drugs in Korea. We enrolled 5802 subjects who had results of HLA typing test from August 2005 to July 2014. Total 28 SJS/TEN patients were categorized based on culprit drugs (allopurinol, lamotrigine, carbamazepine) and identified the presence of HLA-B*58:01, HLA-B*44:03, HLA-B*15:02, and HLA-A*31:01. HLA-A*24:02 (20.5%), HLA-B*44:03 (10.0%), and HLA-Cw*01:02 (17.1%) were the most frequent type in HLA-A, -B, and -C genes, respectively. Allele frequencies of HLA-B*58:01, HLA-B*44:03, HLA-A*31:01, and HLA-B*15:02 were 7.0%, 10.0%, 5.0%, and 0.3%, respectively. In 958 allopurinol users, 9 subjects (0.9%) were diagnosed with SJS/TEN. Among them, 8 subjects possessed HLA-B*58:01 allele. SJS/TEN induced by allopurinol was more frequently developed in subjects with HLA-B*58:01 than in subjects without it [odds ratio: 57.4; confidence interval (CI) 7.12-463.50; p<0.001]. Allopurinol treatment, based on screening by HLA-B*58:01 genotyping, could be more cost-effective than that not based on screening. HLA-B*44:03 may be associated with lamotrigine-induced SJS/TEN (odds ratio: 12.75; CI 1.03-157.14; p=0.053). Among carbamazepine users, only two patients experienced SJS/TEN and possessed neither HLA-B*15:02 nor HLA-A*31:03. HLA gene frequencies varied in Korea. Screening of HLA-B*58:01 before the use of allopurinol might be needed to anticipate probability of SJS/TEN. Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) are very serious forms of drug-induced cutaneous adverse reaction. SJS/TEN induced by certain drug is well known to be associated with some human leukocyte antigen (HLA) gene type. We aimed to explore HLA allele frequencies and their association with SJS/TEN according to culprit drugs in Korea.PURPOSEStevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) are very serious forms of drug-induced cutaneous adverse reaction. SJS/TEN induced by certain drug is well known to be associated with some human leukocyte antigen (HLA) gene type. We aimed to explore HLA allele frequencies and their association with SJS/TEN according to culprit drugs in Korea.We enrolled 5802 subjects who had results of HLA typing test from August 2005 to July 2014. Total 28 SJS/TEN patients were categorized based on culprit drugs (allopurinol, lamotrigine, carbamazepine) and identified the presence of HLA-B*58:01, HLA-B*44:03, HLA-B*15:02, and HLA-A*31:01.MATERIALS AND METHODSWe enrolled 5802 subjects who had results of HLA typing test from August 2005 to July 2014. Total 28 SJS/TEN patients were categorized based on culprit drugs (allopurinol, lamotrigine, carbamazepine) and identified the presence of HLA-B*58:01, HLA-B*44:03, HLA-B*15:02, and HLA-A*31:01.HLA-A*24:02 (20.5%), HLA-B*44:03 (10.0%), and HLA-Cw*01:02 (17.1%) were the most frequent type in HLA-A, -B, and -C genes, respectively. Allele frequencies of HLA-B*58:01, HLA-B*44:03, HLA-A*31:01, and HLA-B*15:02 were 7.0%, 10.0%, 5.0%, and 0.3%, respectively. In 958 allopurinol users, 9 subjects (0.9%) were diagnosed with SJS/TEN. Among them, 8 subjects possessed HLA-B*58:01 allele. SJS/TEN induced by allopurinol was more frequently developed in subjects with HLA-B*58:01 than in subjects without it [odds ratio: 57.4; confidence interval (CI) 7.12-463.50; p<0.001]. Allopurinol treatment, based on screening by HLA-B*58:01 genotyping, could be more cost-effective than that not based on screening. HLA-B*44:03 may be associated with lamotrigine-induced SJS/TEN (odds ratio: 12.75; CI 1.03-157.14; p=0.053). Among carbamazepine users, only two patients experienced SJS/TEN and possessed neither HLA-B*15:02 nor HLA-A*31:03.RESULTSHLA-A*24:02 (20.5%), HLA-B*44:03 (10.0%), and HLA-Cw*01:02 (17.1%) were the most frequent type in HLA-A, -B, and -C genes, respectively. Allele frequencies of HLA-B*58:01, HLA-B*44:03, HLA-A*31:01, and HLA-B*15:02 were 7.0%, 10.0%, 5.0%, and 0.3%, respectively. In 958 allopurinol users, 9 subjects (0.9%) were diagnosed with SJS/TEN. Among them, 8 subjects possessed HLA-B*58:01 allele. SJS/TEN induced by allopurinol was more frequently developed in subjects with HLA-B*58:01 than in subjects without it [odds ratio: 57.4; confidence interval (CI) 7.12-463.50; p<0.001]. Allopurinol treatment, based on screening by HLA-B*58:01 genotyping, could be more cost-effective than that not based on screening. HLA-B*44:03 may be associated with lamotrigine-induced SJS/TEN (odds ratio: 12.75; CI 1.03-157.14; p=0.053). Among carbamazepine users, only two patients experienced SJS/TEN and possessed neither HLA-B*15:02 nor HLA-A*31:03.HLA gene frequencies varied in Korea. Screening of HLA-B*58:01 before the use of allopurinol might be needed to anticipate probability of SJS/TEN.CONCLUSIONHLA gene frequencies varied in Korea. Screening of HLA-B*58:01 before the use of allopurinol might be needed to anticipate probability of SJS/TEN. |
Author | Kim, Young Joo Park, Jung-Won Park, Hye Jung Lee, Jae-Hyun Kim, Junho Kim, Dong Hyun Park, Kyung Hee |
AuthorAffiliation | Division of Allergy and Immunology, Department of Internal Medicine, Institute of Allergy, Yonsei University College of Medicine, Seoul, Korea |
AuthorAffiliation_xml | – name: Division of Allergy and Immunology, Department of Internal Medicine, Institute of Allergy, Yonsei University College of Medicine, Seoul, Korea |
Author_xml | – sequence: 1 givenname: Hye Jung surname: Park fullname: Park, Hye Jung organization: Division of Allergy and Immunology, Department of Internal Medicine, Institute of Allergy, Yonsei University College of Medicine, Seoul, Korea – sequence: 2 givenname: Young Joo surname: Kim fullname: Kim, Young Joo organization: Division of Allergy and Immunology, Department of Internal Medicine, Institute of Allergy, Yonsei University College of Medicine, Seoul, Korea – sequence: 3 givenname: Dong Hyun surname: Kim fullname: Kim, Dong Hyun organization: Division of Allergy and Immunology, Department of Internal Medicine, Institute of Allergy, Yonsei University College of Medicine, Seoul, Korea – sequence: 4 givenname: Junho surname: Kim fullname: Kim, Junho organization: Division of Allergy and Immunology, Department of Internal Medicine, Institute of Allergy, Yonsei University College of Medicine, Seoul, Korea – sequence: 5 givenname: Kyung Hee surname: Park fullname: Park, Kyung Hee organization: Division of Allergy and Immunology, Department of Internal Medicine, Institute of Allergy, Yonsei University College of Medicine, Seoul, Korea – sequence: 6 givenname: Jung-Won surname: Park fullname: Park, Jung-Won organization: Division of Allergy and Immunology, Department of Internal Medicine, Institute of Allergy, Yonsei University College of Medicine, Seoul, Korea – sequence: 7 givenname: Jae-Hyun surname: Lee fullname: Lee, Jae-Hyun organization: Division of Allergy and Immunology, Department of Internal Medicine, Institute of Allergy, Yonsei University College of Medicine, Seoul, Korea |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/26632391$$D View this record in MEDLINE/PubMed https://www.kci.go.kr/kciportal/ci/sereArticleSearch/ciSereArtiView.kci?sereArticleSearchBean.artiId=ART002059294$$DAccess content in National Research Foundation of Korea (NRF) |
BookMark | eNp1kUtvEzEUhS1URNPCD2CDvGQzqa89tmdYII1CXxCBRANby_F4UrcTO9gzoPz7Og3hJbG6kv2dc659TtCRD94i9BLIlLGyPtuu76aUgJhyOYUpQPUETaCWoqAlk0doQjiwgstaHKOTlO4IoRIIfYaOqRCMshomyF_NG9z0ve0tvoj222i9cTZh5zGvCMUfQrTapzf4q47Otgd0sd1kqEkpGKeHfP7DDbf45v3N2eL8I26MCbF1foWHgGdjv4luwO_iuErP0dNO98m--DlP0ZeL88Xsqph_uryeNfPClIwORdXKlstWwLKuJKOUi67lIABIlZ-2tBREBbTWlkgquOnkkhBdVtLUBnRVCXaKXu99fezUvXEqaPc4V0HdR9V8XlwrxsgefbtHN-NybVtj_RB1r_LOax23j8K_b7y7zTbfVSlqUZf0d9Ymhvx_aVBrl4zte-1tGJMCWZaC18BZRl_9mfUr5NBHBuQeMDGkFG2njBv04MIu2vUKiNo1r3Lzate84lKBys1nJfyjPJj_X_MAgJOvXg |
CitedBy_id | crossref_primary_10_1038_s43018_023_00561_8 crossref_primary_10_17816_dv625526 crossref_primary_10_3341_jkos_2021_62_6_842 crossref_primary_10_15263_jlmqa_2024_46_1_1 crossref_primary_10_3390_diagnostics11091611 crossref_primary_10_1186_s13321_017_0202_6 crossref_primary_10_1002_jcph_2040 crossref_primary_10_1007_s00403_021_02258_3 crossref_primary_10_1136_bjophthalmol_2020_317105 crossref_primary_10_1016_j_iac_2022_01_006 crossref_primary_10_1038_s12276_023_00952_y crossref_primary_10_1097_FPC_0000000000000397 crossref_primary_10_1016_j_jaip_2019_05_047 crossref_primary_10_1371_journal_pone_0296498 crossref_primary_10_12688_f1000research_24748_1 crossref_primary_10_1016_j_coi_2016_05_003 crossref_primary_10_1016_j_trim_2023_101859 crossref_primary_10_1111_1346_8138_17692 crossref_primary_10_1186_s13321_018_0257_z crossref_primary_10_3389_fphar_2022_891838 crossref_primary_10_1097_ACI_0000000000000914 crossref_primary_10_1002_stem_2865 crossref_primary_10_1097_CM9_0000000000003250 crossref_primary_10_18632_oncotarget_13250 crossref_primary_10_1016_j_bbmt_2020_05_008 crossref_primary_10_1186_s13023_017_0566_8 crossref_primary_10_1007_s12016_017_8654_z crossref_primary_10_1016_j_braindev_2018_05_005 crossref_primary_10_2217_pgs_2021_0041 crossref_primary_10_1016_j_seizure_2021_07_011 crossref_primary_10_1097_FPC_0000000000000531 crossref_primary_10_3389_fimmu_2021_661135 crossref_primary_10_1016_j_heliyon_2024_e33976 crossref_primary_10_1002_pds_4774 crossref_primary_10_3389_fmed_2023_1238405 crossref_primary_10_1080_14740338_2020_1796965 crossref_primary_10_1007_s12687_024_00753_4 crossref_primary_10_3389_fmed_2021_640360 crossref_primary_10_2217_pme_2022_0126 crossref_primary_10_12793_tcp_2016_24_3_143 crossref_primary_10_15324_kjcls_2024_56_3_236 crossref_primary_10_1111_jdv_16339 crossref_primary_10_1186_s13046_021_02034_1 crossref_primary_10_12677_acm_2024_1492540 crossref_primary_10_5483_BMBRep_2022_55_9_077 crossref_primary_10_3389_fphar_2017_00879 crossref_primary_10_1111_jcpt_13616 crossref_primary_10_1016_j_jhep_2019_03_018 crossref_primary_10_3349_ymj_2019_60_2_208 crossref_primary_10_3389_fphar_2024_1423636 crossref_primary_10_1097_FPC_0000000000000306 crossref_primary_10_1002_advs_202409919 crossref_primary_10_3389_fmed_2021_644871 |
Cites_doi | 10.1111/j.1365-2133.2012.10894.x 10.1111/j.1346-8138.2010.01196.x 10.1097/01.bor.0000209435.89720.7c 10.1007/s00134-009-1659-1 10.1038/clpt.2012.189 10.1093/ndt/gfr060 10.1007/978-1-61779-842-9_4 10.3343/kjlm.2010.30.6.685 10.1038/jid.2012.510 10.2217/pgs.11.165 10.1016/j.jaci.2011.12.990 10.1038/nature11147 10.1016/j.eplepsyres.2010.10.006 10.1016/j.eplepsyres.2011.08.010 10.1016/S0300-2977(97)00088-0 10.3349/ymj.2015.56.2.578 10.1111/j.1742-7843.2011.00681.x 10.2217/pgs.09.162 10.1001/archderm.1993.01680220104023 10.1136/adc.2010.190454 10.1159/000335612 10.1038/sj.jid.5701033 10.12788/j.sder.0058 10.1016/j.jaad.2007.08.036 10.1016/j.humimm.2012.07.321 10.1097/FPC.0b013e32832c347d 10.2217/pgs.12.89 10.1097/FPC.0b013e328330a3b8 10.1111/iji.12067 10.1186/1471-2377-13-77 10.1097/ACI.0b013e3282370c5f 10.2217/pgs.10.77 10.1002/acr.21772 10.1038/tpj.2013.40 10.1093/hmg/ddq537 10.1097/FPC.0b013e3282f3ef9c 10.1007/s00228-014-1764-0 10.1097/FPC.0b013e32834282b8 10.1111/j.1399-0039.2005.00386.x |
ContentType | Journal Article |
Copyright | Copyright: Yonsei University College of Medicine 2016 2016 |
Copyright_xml | – notice: Copyright: Yonsei University College of Medicine 2016 2016 |
DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM 7X8 5PM ACYCR |
DOI | 10.3349/ymj.2016.57.1.118 |
DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic PubMed Central (Full Participant titles) Korean Citation Index |
DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
DatabaseTitleList | MEDLINE MEDLINE - Academic |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine |
EISSN | 1976-2437 |
EndPage | 126 |
ExternalDocumentID | oai_kci_go_kr_ARTI_330886 PMC4696942 26632391 10_3349_ymj_2016_57_1_118 |
Genre | Research Support, Non-U.S. Gov't Journal Article |
GeographicLocations | Republic of Korea |
GeographicLocations_xml | – name: Republic of Korea |
GrantInformation_xml | – fundername: ; |
GroupedDBID | --- .55 .GJ 123 29R 2WC 36B 5-W 53G 5RE 8JR 8XY 9ZL AAYXX ACYCR ADBBV ADRAZ AEGXH AENEX ALMA_UNASSIGNED_HOLDINGS AOIJS BAWUL BCNDV CITATION CS3 DIK DU5 E3Z EBD EF. EMB EMOBN F5P GROUPED_DOAJ GX1 HYE KQ8 L7B M48 MK0 O5R O5S OK1 OVT P2P PGMZT RNS RPM SV3 TR2 X7M XSB ZGI ZXP CGR CUY CVF ECM EIF NPM 7X8 5PM |
ID | FETCH-LOGICAL-c432t-8d7d57d61b98732256fd5161108243be2168129ae07265cf7b00a487c9c1a8863 |
IEDL.DBID | M48 |
ISSN | 0513-5796 1976-2437 |
IngestDate | Sun Mar 09 07:50:53 EDT 2025 Thu Aug 21 17:52:13 EDT 2025 Fri Jul 11 04:59:40 EDT 2025 Mon Jul 21 06:01:12 EDT 2025 Tue Jul 01 04:03:00 EDT 2025 Thu Apr 24 23:03:45 EDT 2025 |
IsDoiOpenAccess | true |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 1 |
Keywords | Stevens-Johnson syndrome HLA-B58:01 human leukocyte antigen Allopurinol toxic epidermal necrolysis |
Language | English |
License | http://creativecommons.org/licenses/by-nc/3.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c432t-8d7d57d61b98732256fd5161108243be2168129ae07265cf7b00a487c9c1a8863 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 Hye Jung Park and Young Joo Kim contributed equally to this work. http://ymj.kr/DOIx.php?id=10.3349/ymj.2016.57.1.118 G704-000409.2016.57.1.007 |
OpenAccessLink | http://journals.scholarsportal.info/openUrl.xqy?doi=10.3349/ymj.2016.57.1.118 |
PMID | 26632391 |
PQID | 1744659153 |
PQPubID | 23479 |
PageCount | 9 |
ParticipantIDs | nrf_kci_oai_kci_go_kr_ARTI_330886 pubmedcentral_primary_oai_pubmedcentral_nih_gov_4696942 proquest_miscellaneous_1744659153 pubmed_primary_26632391 crossref_citationtrail_10_3349_ymj_2016_57_1_118 crossref_primary_10_3349_ymj_2016_57_1_118 |
ProviderPackageCode | CITATION AAYXX |
PublicationCentury | 2000 |
PublicationDate | 2016-01-01 |
PublicationDateYYYYMMDD | 2016-01-01 |
PublicationDate_xml | – month: 01 year: 2016 text: 2016-01-01 day: 01 |
PublicationDecade | 2010 |
PublicationPlace | Korea (South) |
PublicationPlace_xml | – name: Korea (South) |
PublicationTitle | Yonsei medical journal |
PublicationTitleAlternate | Yonsei Med J |
PublicationYear | 2016 |
Publisher | Yonsei University College of Medicine 연세대학교의과대학 |
Publisher_xml | – name: Yonsei University College of Medicine – name: 연세대학교의과대학 |
References | Kim (10.3349/ymj.2016.57.1.118_ref16) 2011; 97 Struck (10.3349/ymj.2016.57.1.118_ref2) 2010; 36 Illing (10.3349/ymj.2016.57.1.118_ref7) 2012; 486 Chung (10.3349/ymj.2016.57.1.118_ref32) 2007; 7 Park (10.3349/ymj.2016.57.1.118_ref13) 2015; 71 Wei (10.3349/ymj.2016.57.1.118_ref6) 2012; 129 Mockenhaupt (10.3349/ymj.2016.57.1.118_ref21) 2014; 33 Sekula (10.3349/ymj.2016.57.1.118_ref4) 2013; 133 Ganesan (10.3349/ymj.2016.57.1.118_ref11) 2011; 96 Lee (10.3349/ymj.2016.57.1.118_ref40) 2005; 65 Phillips (10.3349/ymj.2016.57.1.118_ref24) 2009; 11 Hung (10.3349/ymj.2016.57.1.118_ref14) 2010; 11 Mockenhaupt (10.3349/ymj.2016.57.1.118_ref1) 2012; 97 Yip (10.3349/ymj.2016.57.1.118_ref35) 2012; 92 An (10.3349/ymj.2016.57.1.118_ref39) 2010; 92 Chung (10.3349/ymj.2016.57.1.118_ref19) 2010; 30 Kazeem (10.3349/ymj.2016.57.1.118_ref36) 2009; 19 Shi (10.3349/ymj.2016.57.1.118_ref38) 2011; 109 Ozeki (10.3349/ymj.2016.57.1.118_ref34) 2011; 20 Bastuji-Garin (10.3349/ymj.2016.57.1.118_ref3) 1993; 129 Halevy (10.3349/ymj.2016.57.1.118_ref30) 2008; 58 Huh (10.3349/ymj.2016.57.1.118_ref18) 2013; 40 Mockenhaupt (10.3349/ymj.2016.57.1.118_ref5) 2008; 128 Genin (10.3349/ymj.2016.57.1.118_ref12) 2014; 14 Phillips (10.3349/ymj.2016.57.1.118_ref25) 2010; 11 Tassaneeyakul (10.3349/ymj.2016.57.1.118_ref33) 2009; 19 Park (10.3349/ymj.2016.57.1.118_ref27) 2015; 56 Pluim (10.3349/ymj.2016.57.1.118_ref29) 1998; 52 Khanna (10.3349/ymj.2016.57.1.118_ref31) 2012; 64 Cao (10.3349/ymj.2016.57.1.118_ref8) 2012; 13 McCormack (10.3349/ymj.2016.57.1.118_ref37) 2012; 13 Trajanoski (10.3349/ymj.2016.57.1.118_ref20) 2012; 882 Dong (10.3349/ymj.2016.57.1.118_ref23) 2012; 73 Chiu (10.3349/ymj.2016.57.1.118_ref9) 2012; 167 Kang (10.3349/ymj.2016.57.1.118_ref17) 2011; 21 Lonjou (10.3349/ymj.2016.57.1.118_ref10) 2008; 18 Jung (10.3349/ymj.2016.57.1.118_ref15) 2011; 26 Aihara (10.3349/ymj.2016.57.1.118_ref26) 2011; 38 Mikuls (10.3349/ymj.2016.57.1.118_ref28) 2006; 18 Balnyte (10.3349/ymj.2016.57.1.118_ref22) 2013; 13 23132554 - Clin Pharmacol Ther. 2012 Dec;92(6):757-65 23724919 - Int J Immunogenet. 2013 Dec;40(6):515-23 21157157 - Korean J Lab Med. 2010 Dec;30(6):685-96 22613850 - Chem Immunol Allergy. 2012;97:1-17 25327504 - Eur J Clin Pharmacol. 2015 Jan;71(1):35-41 20602616 - Pharmacogenomics. 2010 Jul;11(7):973-87 22379998 - Pharmacogenomics. 2012 Mar;13(4):399-405 19787334 - Intensive Care Med. 2010 Jan;36(1):22-32 21301380 - Pharmacogenet Genomics. 2011 May;21(5):303-7 21917426 - Epilepsy Res. 2011 Nov;97(1-2):190-7 22322005 - J Allergy Clin Immunol. 2012 Jun;129(6):1562-9.e5 20235791 - Pharmacogenomics. 2010 Mar;11(3):349-56 21393610 - Nephrol Dial Transplant. 2011 Nov;26(11):3567-72 22841927 - Hum Immunol. 2012 Oct;73(10):998-1004 17919772 - J Am Acad Dermatol. 2008 Jan;58(1):25-32 8420497 - Arch Dermatol. 1993 Jan;129(1):92-6 21342226 - J Dermatol. 2011 Mar;38(3):246-54 19668019 - Pharmacogenet Genomics. 2009 Sep;19(9):661-5 21149285 - Hum Mol Genet. 2011 Mar 1;20(5):1034-41 21306565 - Basic Clin Pharmacol Toxicol. 2011 Jul;109(1):42-6 23389396 - J Invest Dermatol. 2013 May;133(5):1197-204 9599967 - Neth J Med. 1998 Mar;52(3):107-10 15853898 - Tissue Antigens. 2005 May;65(5):437-47 22665228 - Methods Mol Biol. 2012;882:47-65 25037254 - Semin Cutan Med Surg. 2014 Mar;33(1):10-6 21169235 - Arch Dis Child. 2011 Jan;96(1):104-6 23837503 - BMC Neurol. 2013;13:77 17620823 - Curr Opin Allergy Clin Immunol. 2007 Aug;7(4):317-23 21071176 - Epilepsy Res. 2010 Dec;92(2-3):226-30 16462529 - Curr Opin Rheumatol. 2006 Mar;18(2):199-203 19479656 - Curr Opin Mol Ther. 2009 Jun;11(3):231-42 18192896 - Pharmacogenet Genomics. 2008 Feb;18(2):99-107 22348415 - Br J Dermatol. 2012 Jul;167(1):44-9 22722860 - Nature. 2012 Jun 28;486(7404):554-8 22909208 - Pharmacogenomics. 2012 Jul;13(10):1193-201 25684012 - Yonsei Med J. 2015 Mar;56(2):578-81 19696695 - Pharmacogenet Genomics. 2009 Sep;19(9):704-9 23024028 - Arthritis Care Res (Hoboken). 2012 Oct;64(10):1431-46 17805350 - J Invest Dermatol. 2008 Jan;128(1):35-44 24322785 - Pharmacogenomics J. 2014 Jun;14(3):281-8 |
References_xml | – volume: 167 start-page: 44 year: 2012 ident: 10.3349/ymj.2016.57.1.118_ref9 publication-title: Br J Dermatol doi: 10.1111/j.1365-2133.2012.10894.x – volume: 38 start-page: 246 year: 2011 ident: 10.3349/ymj.2016.57.1.118_ref26 publication-title: J Dermatol doi: 10.1111/j.1346-8138.2010.01196.x – volume: 18 start-page: 199 year: 2006 ident: 10.3349/ymj.2016.57.1.118_ref28 publication-title: Curr Opin Rheumatol doi: 10.1097/01.bor.0000209435.89720.7c – volume: 36 start-page: 22 year: 2010 ident: 10.3349/ymj.2016.57.1.118_ref2 publication-title: Intensive Care Med doi: 10.1007/s00134-009-1659-1 – volume: 92 start-page: 757 year: 2012 ident: 10.3349/ymj.2016.57.1.118_ref35 publication-title: Clin Pharmacol Ther doi: 10.1038/clpt.2012.189 – volume: 26 start-page: 3567 year: 2011 ident: 10.3349/ymj.2016.57.1.118_ref15 publication-title: Nephrol Dial Transplant doi: 10.1093/ndt/gfr060 – volume: 882 start-page: 47 year: 2012 ident: 10.3349/ymj.2016.57.1.118_ref20 publication-title: Methods Mol Biol doi: 10.1007/978-1-61779-842-9_4 – volume: 30 start-page: 685 year: 2010 ident: 10.3349/ymj.2016.57.1.118_ref19 publication-title: Korean J Lab Med doi: 10.3343/kjlm.2010.30.6.685 – volume: 133 start-page: 1197 year: 2013 ident: 10.3349/ymj.2016.57.1.118_ref4 publication-title: J Invest Dermatol doi: 10.1038/jid.2012.510 – volume: 13 start-page: 399 year: 2012 ident: 10.3349/ymj.2016.57.1.118_ref37 publication-title: Pharmacogenomics doi: 10.2217/pgs.11.165 – volume: 129 start-page: 1562 year: 2012 ident: 10.3349/ymj.2016.57.1.118_ref6 publication-title: J Allergy Clin Immunol doi: 10.1016/j.jaci.2011.12.990 – volume: 486 start-page: 554 year: 2012 ident: 10.3349/ymj.2016.57.1.118_ref7 publication-title: Nature doi: 10.1038/nature11147 – volume: 92 start-page: 226 year: 2010 ident: 10.3349/ymj.2016.57.1.118_ref39 publication-title: Epilepsy Res doi: 10.1016/j.eplepsyres.2010.10.006 – volume: 97 start-page: 190 year: 2011 ident: 10.3349/ymj.2016.57.1.118_ref16 publication-title: Epilepsy Res doi: 10.1016/j.eplepsyres.2011.08.010 – volume: 52 start-page: 107 year: 1998 ident: 10.3349/ymj.2016.57.1.118_ref29 publication-title: Neth J Med doi: 10.1016/S0300-2977(97)00088-0 – volume: 56 start-page: 578 year: 2015 ident: 10.3349/ymj.2016.57.1.118_ref27 publication-title: Yonsei Med J doi: 10.3349/ymj.2015.56.2.578 – volume: 109 start-page: 42 year: 2011 ident: 10.3349/ymj.2016.57.1.118_ref38 publication-title: Basic Clin Pharmacol Toxicol doi: 10.1111/j.1742-7843.2011.00681.x – volume: 11 start-page: 349 year: 2010 ident: 10.3349/ymj.2016.57.1.118_ref14 publication-title: Pharmacogenomics doi: 10.2217/pgs.09.162 – volume: 129 start-page: 92 year: 1993 ident: 10.3349/ymj.2016.57.1.118_ref3 publication-title: Arch Dermatol doi: 10.1001/archderm.1993.01680220104023 – volume: 11 start-page: 231 year: 2009 ident: 10.3349/ymj.2016.57.1.118_ref24 publication-title: Curr Opin Mol Ther – volume: 96 start-page: 104 year: 2011 ident: 10.3349/ymj.2016.57.1.118_ref11 publication-title: Arch Dis Child doi: 10.1136/adc.2010.190454 – volume: 97 start-page: 1 year: 2012 ident: 10.3349/ymj.2016.57.1.118_ref1 publication-title: Chem Immunol Allergy doi: 10.1159/000335612 – volume: 128 start-page: 35 year: 2008 ident: 10.3349/ymj.2016.57.1.118_ref5 publication-title: J Invest Dermatol doi: 10.1038/sj.jid.5701033 – volume: 33 start-page: 10 year: 2014 ident: 10.3349/ymj.2016.57.1.118_ref21 publication-title: Semin Cutan Med Surg doi: 10.12788/j.sder.0058 – volume: 58 start-page: 25 year: 2008 ident: 10.3349/ymj.2016.57.1.118_ref30 publication-title: J Am Acad Dermatol doi: 10.1016/j.jaad.2007.08.036 – volume: 73 start-page: 998 year: 2012 ident: 10.3349/ymj.2016.57.1.118_ref23 publication-title: Hum Immunol doi: 10.1016/j.humimm.2012.07.321 – volume: 19 start-page: 661 year: 2009 ident: 10.3349/ymj.2016.57.1.118_ref36 publication-title: Pharmacogenet Genomics doi: 10.1097/FPC.0b013e32832c347d – volume: 13 start-page: 1193 year: 2012 ident: 10.3349/ymj.2016.57.1.118_ref8 publication-title: Pharmacogenomics doi: 10.2217/pgs.12.89 – volume: 19 start-page: 704 year: 2009 ident: 10.3349/ymj.2016.57.1.118_ref33 publication-title: Pharmacogenet Genomics doi: 10.1097/FPC.0b013e328330a3b8 – volume: 40 start-page: 515 year: 2013 ident: 10.3349/ymj.2016.57.1.118_ref18 publication-title: Int J Immunogenet doi: 10.1111/iji.12067 – volume: 13 start-page: 77 year: 2013 ident: 10.3349/ymj.2016.57.1.118_ref22 publication-title: BMC Neurol doi: 10.1186/1471-2377-13-77 – volume: 7 start-page: 317 year: 2007 ident: 10.3349/ymj.2016.57.1.118_ref32 publication-title: Curr Opin Allergy Clin Immunol doi: 10.1097/ACI.0b013e3282370c5f – volume: 11 start-page: 973 year: 2010 ident: 10.3349/ymj.2016.57.1.118_ref25 publication-title: Pharmacogenomics doi: 10.2217/pgs.10.77 – volume: 64 start-page: 1431 year: 2012 ident: 10.3349/ymj.2016.57.1.118_ref31 publication-title: Arthritis Care Res (Hoboken) doi: 10.1002/acr.21772 – volume: 14 start-page: 281 year: 2014 ident: 10.3349/ymj.2016.57.1.118_ref12 publication-title: Pharmacogenomics J doi: 10.1038/tpj.2013.40 – volume: 20 start-page: 1034 year: 2011 ident: 10.3349/ymj.2016.57.1.118_ref34 publication-title: Hum Mol Genet doi: 10.1093/hmg/ddq537 – volume: 18 start-page: 99 year: 2008 ident: 10.3349/ymj.2016.57.1.118_ref10 publication-title: Pharmacogenet Genomics doi: 10.1097/FPC.0b013e3282f3ef9c – volume: 71 start-page: 35 year: 2015 ident: 10.3349/ymj.2016.57.1.118_ref13 publication-title: Eur J Clin Pharmacol doi: 10.1007/s00228-014-1764-0 – volume: 21 start-page: 303 year: 2011 ident: 10.3349/ymj.2016.57.1.118_ref17 publication-title: Pharmacogenet Genomics doi: 10.1097/FPC.0b013e32834282b8 – volume: 65 start-page: 437 year: 2005 ident: 10.3349/ymj.2016.57.1.118_ref40 publication-title: Tissue Antigens doi: 10.1111/j.1399-0039.2005.00386.x – reference: 17919772 - J Am Acad Dermatol. 2008 Jan;58(1):25-32 – reference: 21917426 - Epilepsy Res. 2011 Nov;97(1-2):190-7 – reference: 23024028 - Arthritis Care Res (Hoboken). 2012 Oct;64(10):1431-46 – reference: 25684012 - Yonsei Med J. 2015 Mar;56(2):578-81 – reference: 23389396 - J Invest Dermatol. 2013 May;133(5):1197-204 – reference: 23724919 - Int J Immunogenet. 2013 Dec;40(6):515-23 – reference: 19696695 - Pharmacogenet Genomics. 2009 Sep;19(9):704-9 – reference: 22841927 - Hum Immunol. 2012 Oct;73(10):998-1004 – reference: 22379998 - Pharmacogenomics. 2012 Mar;13(4):399-405 – reference: 21342226 - J Dermatol. 2011 Mar;38(3):246-54 – reference: 19668019 - Pharmacogenet Genomics. 2009 Sep;19(9):661-5 – reference: 21149285 - Hum Mol Genet. 2011 Mar 1;20(5):1034-41 – reference: 19787334 - Intensive Care Med. 2010 Jan;36(1):22-32 – reference: 20602616 - Pharmacogenomics. 2010 Jul;11(7):973-87 – reference: 22722860 - Nature. 2012 Jun 28;486(7404):554-8 – reference: 25327504 - Eur J Clin Pharmacol. 2015 Jan;71(1):35-41 – reference: 25037254 - Semin Cutan Med Surg. 2014 Mar;33(1):10-6 – reference: 22348415 - Br J Dermatol. 2012 Jul;167(1):44-9 – reference: 21306565 - Basic Clin Pharmacol Toxicol. 2011 Jul;109(1):42-6 – reference: 17620823 - Curr Opin Allergy Clin Immunol. 2007 Aug;7(4):317-23 – reference: 21071176 - Epilepsy Res. 2010 Dec;92(2-3):226-30 – reference: 8420497 - Arch Dermatol. 1993 Jan;129(1):92-6 – reference: 9599967 - Neth J Med. 1998 Mar;52(3):107-10 – reference: 21301380 - Pharmacogenet Genomics. 2011 May;21(5):303-7 – reference: 23132554 - Clin Pharmacol Ther. 2012 Dec;92(6):757-65 – reference: 15853898 - Tissue Antigens. 2005 May;65(5):437-47 – reference: 21393610 - Nephrol Dial Transplant. 2011 Nov;26(11):3567-72 – reference: 17805350 - J Invest Dermatol. 2008 Jan;128(1):35-44 – reference: 21157157 - Korean J Lab Med. 2010 Dec;30(6):685-96 – reference: 22665228 - Methods Mol Biol. 2012;882:47-65 – reference: 19479656 - Curr Opin Mol Ther. 2009 Jun;11(3):231-42 – reference: 21169235 - Arch Dis Child. 2011 Jan;96(1):104-6 – reference: 22613850 - Chem Immunol Allergy. 2012;97:1-17 – reference: 22909208 - Pharmacogenomics. 2012 Jul;13(10):1193-201 – reference: 18192896 - Pharmacogenet Genomics. 2008 Feb;18(2):99-107 – reference: 20235791 - Pharmacogenomics. 2010 Mar;11(3):349-56 – reference: 22322005 - J Allergy Clin Immunol. 2012 Jun;129(6):1562-9.e5 – reference: 16462529 - Curr Opin Rheumatol. 2006 Mar;18(2):199-203 – reference: 23837503 - BMC Neurol. 2013;13:77 – reference: 24322785 - Pharmacogenomics J. 2014 Jun;14(3):281-8 |
SSID | ssj0027102 |
Score | 2.3349533 |
Snippet | Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) are very serious forms of drug-induced cutaneous adverse reaction. SJS/TEN induced by... Purpose: Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) are very serious forms of drug-induced cutaneousadverse reaction. SJS/TEN induced... |
SourceID | nrf pubmedcentral proquest pubmed crossref |
SourceType | Open Website Open Access Repository Aggregation Database Index Database Enrichment Source |
StartPage | 118 |
SubjectTerms | Adult Aged Alleles Allopurinol - adverse effects Allopurinol - pharmacology Anticonvulsants - adverse effects Asian Continental Ancestry Group - genetics Carbamazepine - adverse effects Carbamazepine - pharmacology Case-Control Studies Drug-Related Side Effects and Adverse Reactions - genetics Drug-Related Side Effects and Adverse Reactions - immunology Female Gene Frequency Genetic Predisposition to Disease Genotype HLA-B Antigens - genetics Humans Male Middle Aged Odds Ratio Original Polymorphism, Single Nucleotide Republic of Korea Retrospective Studies Risk Factors Stevens-Johnson Syndrome - ethnology Stevens-Johnson Syndrome - etiology Stevens-Johnson Syndrome - genetics Triazines - adverse effects Triazines - pharmacology 의학일반 |
Title | HLA Allele Frequencies in 5802 Koreans: Varied Allele Types Associated with SJS/TEN According to Culprit Drugs |
URI | https://www.ncbi.nlm.nih.gov/pubmed/26632391 https://www.proquest.com/docview/1744659153 https://pubmed.ncbi.nlm.nih.gov/PMC4696942 https://www.kci.go.kr/kciportal/ci/sereArticleSearch/ciSereArtiView.kci?sereArticleSearchBean.artiId=ART002059294 |
Volume | 57 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
ispartofPNX | Yonsei Medical Journal, 2016, 57(1), , pp.118-126 |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV1bb9MwFLbWISFe0MZt3VhlJJ6Q0tWJb0FCqBqrymB72Qp7s3JxR1lwtiSV2L_nnFwKRRUST1ESJ1b8-eR8ny_nEPJaRkGaAG_wtI_TjJb7Xox7ZRJuRyqdyzRI6mif53I646dX4mqLdOmt2gYsN0o7zCc1K7Lhz7v792Dw71BxBjw8uv_xHddoyaFQQwb_AN0jD8AxKczkcMb1b_3F6iWI0A0DD7dgNpOcm1-x5qZ6rphvYqB_L6T8wzNNdsjjllLScdMHdsmWdU_Iw7N20vwpcdPPYzrOMnAwdFI0S6dBH9OFo0KPfPopB-Loyrf0C-rmtCuKCrWkHXxwHYds6cXpxdHlyTnFLBMF-j1a5fR4md0Wi4p-KJbX5TMym5xcHk-9Ns0CABL4ladTlQqVShaHWqF9y3kqgAgyYAc8iK3PMEZZGAF4vhTJXIGlRqBzkjBhkdYyeE62Xe7sHqFaxdZGDKMKjniQAHtUQJdEaP0YjV31yahrVZO0McgxFUZmQIsgEAaAMAiEEcowkCe6T96sHrltAnD8q_ArgMrcJAuDYbPxeJ2bm8KAOPgIz8AvVUKZDkgDpoTzI5Gz-bI0IM64FCH4gD550QC7qhJ4TAC9mfWJWoN8VQDrW7_jFt_qcN1chjLk_v7_fMgBeYTnzVjPS7JdFUt7COynigekJ7yvg3rsYFD371_Su_6n |
linkProvider | Scholars Portal |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=HLA+Allele+Frequencies+in+5802+Koreans%3A+Varied+Allele+Types+Associated+with+SJS%2FTEN+According+to+Culprit+Drugs&rft.jtitle=Yonsei+medical+journal&rft.au=Park%2C+Hye+Jung&rft.au=Kim%2C+Young+Joo&rft.au=Kim%2C+Dong+Hyun&rft.au=Kim%2C+Junho&rft.date=2016-01-01&rft.issn=0513-5796&rft.eissn=1976-2437&rft.volume=57&rft.issue=1&rft.spage=118&rft_id=info:doi/10.3349%2Fymj.2016.57.1.118&rft.externalDBID=n%2Fa&rft.externalDocID=10_3349_ymj_2016_57_1_118 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0513-5796&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0513-5796&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0513-5796&client=summon |